U.S. markets closed
  • S&P 500

    +51.87 (+1.60%)
  • Dow 30

    +358.56 (+1.34%)
  • Nasdaq

    +241.26 (+2.26%)
  • Russell 2000

    +23.09 (+1.59%)
  • Crude Oil

    -0.27 (-0.67%)
  • Gold

    -12.60 (-0.67%)
  • Silver

    -0.21 (-0.91%)

    -0.0038 (-0.33%)
  • 10-Yr Bond

    -0.0070 (-1.05%)

    -0.0007 (-0.06%)

    +0.0980 (+0.09%)

    -51.84 (-0.48%)
  • CMC Crypto 200

    +12.36 (+5.67%)
  • FTSE 100

    +19.89 (+0.34%)
  • Nikkei 225

    +116.82 (+0.51%)

US STOCKS-S&P 500 rises on optimism over COVID-19 vaccine, stimulus

Devik Jain and Medha Singh

(For a live blog on the U.S. stock market, click or type LIVE/ in a news window.)

* Chevron slips after agreeing to buy Noble Energy for $5 bln

* Halliburton rises after results

* Pfizer up on securing UK supply deal for potential vaccines

* Dow down 0.23%, S&P up 0.24%, Nasdaq rises 1.17% (Adds quote, details; updates prices)

By Devik Jain and Medha Singh

July 20 (Reuters) - The S&P 500 edged higher on Monday as promising data across a range of COVID-19 vaccine candidates and hopes of more stimulus helped overcome fears around the extent of the economic damage from a surge in domestic coronavirus infections.

The Nasdaq gained 1.2%, boosted by a 4% jump in Amazon.com Inc as two brokerages raised their price targets on the online retail giant's shares. Microsoft Corp, which is set to report quarterly results later this week, also rose 2.0%.

The Dow was weighed down by industrial conglomerate 3M Co .

U.S. drugmaker Pfizer and German biotech firm BioNTech reported additional data from their experimental COVID-19 vaccine that showed it was safe and induced an immune response in patients. Pfizer's shares rose 1.3%.

In the United Kingdom, data from AstraZeneca's experimental COVID-19 vaccine also showed it produced an immune response in early-stage clinical trials in healthy volunteers.

"Even though we had some good vaccine news, the Phase-3 trials for many of these things is the hardest part and is very difficult to get through," said Elliott Savage, portfolio manager of the YCG Enhanced Fund in Austin, Texas.

"At this point, the fiscal stimulus is the next thing on investors' mind. If there were a big audacious kind of fiscal stimulus package, then that could definitely cause the market to move higher."

Congress is set to debate a new aid package this week with some support programmes due to expire by the end of the month. Record levels of new COVID-19 cases are also forcing many states to back-pedal their reopening plans.

Signs of progress on a potential coronavirus vaccine, improving economic data and a relatively upbeat start to the second-quarter earnings season helped the S&P 500 and the Dow rise for three consecutive weeks.

The benchmark S&P 500 is now about 5% down from its Feb. 19 record close.

At 11:22 a.m. ET, the Dow Jones Industrial Average was down 61.15 points, or 0.23%, at 26,610.80 and the S&P 500 was up 7.83 points, or 0.24%, at 3,232.56. The Nasdaq Composite was up 123.26 points, or 1.17%, at 10,626.45.

Technology and consumer discretionary rose more than any other S&P sector, while energy and industrials lagged.

Oilfield services giant Halliburton Co rose 6.4% as it posted a surprise adjusted profit, benefiting from aggressive cost cuts.

Noble Energy Inc's shares jumped 5% as Chevron Corp agreed to buy the Houston-based oil and gas producer for $5 billion in an all-stock deal. Chevron fell 1.6%.

This week, Tesla Inc, Intel Corp and Honeywell International Inc are expected to report their quarterly results.

Declining issues outnumbered advancers for a 1.28-to-1 ratio on the NYSE and nearly matched advancers on the Nasdaq.

The S&P index recorded 37 new 52-week highs and no new low, while the Nasdaq recorded 102 new highs and nine new lows. (Reporting by Devik Jain and Medha Singh in Bengaluru; Editing by Saumyadeb Chakrabarty and Maju Samuel)